Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in β-blocker users

Clinical Pharmacology and Therapeutics

Volumn 85, Issue 1, 2009, Pages 45-50

  Bijl, M J ^a   Visser, L E ^a   Van Schaik, R H N ^a   Kors, J A ^a   Witteman, J C M ^a   Hofman, A ^a   Vulto, A G ^a   Van Gelder, T ^a   Stricker, B H Ch ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Drug Safety Unit   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CYTOCHROME P450 2D6; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METOPROLOL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BRADYCARDIA; DIASTOLIC BLOOD PRESSURE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADRENERGIC BETA-ANTAGONISTS; AGED; BLOOD PRESSURE; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 CYP2D6; FEMALE; GENETICS, POPULATION; GENOTYPE; HEART RATE; HUMANS; HYPERTENSION; MALE; METOPROLOL; NETHERLANDS; POLYMORPHISM, GENETIC;

EID: 57749198655     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.172     Document Type: Article

References (21)

1. Regårdh, C.G. & Johnsson, G. Clinical pharmacokinetics of metoprolol. Clin. Pharmacokinet. 5, 557-569 (1980).
2. Lennard, M.S., Silas, J.H., Freestone, S., Ramsay, L.E., Tucker, G.T. & Woods, H.F. Oxidation phenotype - a major determinant of metoprolol metabolism and response. N. Engl. J. Med. 307, 1558-1560 (1982).
3. Flockhart, D.A. Drug Interactions: Cytochrome P450 drug interaction table. Indiana University School of Medicine (2007) 〈http:// medicine.iupui.edu/flockhart/table.htm〉. Accessed 18 April 2008.
4. Wuttke, H., Rau, T. & Eschenhagen, T. Genetic polymorphisms in drug metabolizing enzymes - impact on treatment with β-blockers. Dtsch. Med. Wochenschr. 129, 831-835 (2004).
5. Lennard, M.S., Tucker, G.T., Silas, J.H. & Woods, H.F. Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol. Xenobiotica 16, 435-447 (1986).
6. Gaedigk, A., Simon, S., Pearce, R., Bradford, L., Kennedy, M. & Leeder, J. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Mol. Ther. 83, 234-242 (2008).
7. Bradford, L.D. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3, 229-243 (2002).
8. Lennard, M.S., Tucker, G.T. & Woods, H.F. The polymorphic oxidation of β-adrenoceptor antagonists. Clinical pharmacokinetic considerations. Clin. Pharmacokinet. 11, 1-17 (1986).
9. Wuttke, H. et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin. Pharmacol. Ther. 72, 429-437 (2002).
10. Clark, D.W., Morgan, A.K. & Waal-Manning, H. Adverse effects from metoprolol are not generally associated with oxidation status. Br. J. Clin. Pharmacol. 18, 965-967 (1984).
11. Zineh, I. et al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin. Pharmacol. Ther. 76, 536-544 (2004).
12. Fux, R. et al. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin. Pharmacol. Ther. 78, 378-387 (2005).
13. Kirchheiner, J. et al. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 76, 302-312 (2004).
14. Conroy, R.M. et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur. Heart J. 24, 987-1003 (2003).
15. Wiysonge, C.S. et al. β-Blockers for hypertension. Cochrane Database Syst. Rev. CD002003 (2007).
16. Fox, K. et al. Resting heart rate in cardiovascular disease. J. Am. Coll. Cardiol. 50, 823-830 (2007).
17. Rau, T. et al. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics 12, 465-472 (2002).
18. Sjahid, S.I., van der Linden, P.D. & Stricker, B.H. Agreement between the pharmacy medication history and patient interview for cardiovascular drugs: the Rotterdam elderly study. Br. J. Clin. Pharmacol. 45, 591-595 (1998).
19. Hofman, A., Grobbee, D.E., de Jong, P.T. & van den Ouweland, F.A. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur. J. Epidemiol. 7, 403-422 (1991).
20. Hofman, A. et al. The Rotterdam Study: objectives and design update. Eur. J. Epidemiol. 22, 819-829 (2007).
21. Bijl, M.J. et al. Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants. Br. J. Clin. Pharmacol. 65, 558-564 (2008).